For decades, second-line injectable agents (IAs) have been the cornerstone of treatment for
multidrug-resistant tuberculosis (MDR-TB). Although evidence on the efficacy of IAs is …

Bedaquiline (BDQ) has demonstrated potent clinical activity against multidrug-resistant
(MDR) and extensively drug-resistant (XDR) Mycobacterium tuberculosis complex strains [1 …

Background Drug-resistant tuberculosis (DR-TB) remains a major public health concern
worldwide. Bedaquiline, a novel diarylquinoline, was added to the WHO-recommended all …

Background Safety of treatment for multidrug-resistant tuberculosis (MDR/RR-TB) can be an
obstacle to treatment completion. Evaluate safety of longer MDR/RR-TB regimens …

Background India accounts for a quarter of the world's multidrug-resistant tuberculosis (MDR-
TB); with less than 50% having successful treatment outcomes. Bedaquiline (BDQ) was …

Abstract Purpose The Korea Centers for Disease Control & Prevention has implemented a
review process for the approval of new drugs used to treat patients with multidrug-resistant …

Objective To evaluate the cost-effectiveness of adding bedaquiline to a background regimen
(BR) of drugs for multidrug-resistant tuberculosis (MDR-TB) in the United Kingdom (UK) …

Background Bedaquiline is a life-saving tuberculosis drug undergoing global scale-up.
People at risk of weak tuberculosis drug regimens are a priority for novel drug access …

Objectives Bedaquiline treatment significantly improves multidrug-resistant tuberculosis
(MDR-TB) patient treatment outcomes. However, safety and efficacy data are lacking for …

Abstract Background World Health Organization recommends countries introducing new
drug and short treatment regimen for drug resistant tuberculosis (DR-TB) should develop …